Overview

0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The primary objective is to determine the anti-tumor activity of the combination of apricoxib + either docetaxel (AP/DC) or pemetrexed (AP/PE) compared with placebo + either docetaxel (P/DC) or pemetrexed (P/PE) as measured by progression free survival in patients with Stage IIIb (pleural effusion)or Stage IV non-small cell lung cancer (NSCLC).

Phase:

Phase 2

Details

Lead Sponsor:

Martin Edelman, MD
University of Maryland, Baltimore

Collaborator:

Tragara Pharmaceuticals, Inc.

Treatments:

Docetaxel
Pemetrexed